FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I
of a virtual KOL investor event series on Tuesday, February 13,
2024 at 10:30 AM ET. To register, click here.
The event will feature Andrew Ko, MD (University of
California San Francisco (UCSF), UCSF’s Helen Diller Family
Comprehensive Cancer Center) and Vincent Picozzi,
MD, MMM (Virginia Mason Digestive Disease and Cancer Institutes,
Virginia Mason Medical Center), who will discuss the unmet
medical need and current treatment landscape for pancreatic cancer,
as well as the clinical development program for pamrevlumab*, a
potential first-in-class monoclonal antibody targeting connective
tissue growth factor (CTGF) for pancreatic cancer treatment.
The event will include information on the mechanism of action of
pamrevlumab as well as a review of the pre-clinical and Phase 1/2
data for pamrevlumab and the two ongoing trials: the innovative
Precision Promise℠ Phase 2/3 trial being conducted by the
Pancreatic Cancer Action Network (PanCAN) for metastatic pancreatic
cancer, and the LAPIS Phase 3 trial in locally advanced pancreatic
cancer.
A live question and answer will follow the formal
presentations.
The second event in the series, to be scheduled at a later date,
will include a review of the development program for FG-3246; a
Phase 2 ready CD46 targeting antibody-drug conjugate (ADC) for the
treatment of metastatic castration-resistant prostate cancer
(mCRPC).
This series is intended for investor audiences only.
About Andrew Ko, MDAndrew Ko, MD completed his
medical training at the Johns Hopkins School of Medicine
(Baltimore, MD) and Beth Israel Hospital/Harvard Medical School
(Boston, MA) before moving out west to complete his oncology
training at Stanford University. He is currently a Professor of
Medicine and Associate Chief of the Division of Hematology/Oncology
at the University of California San Francisco (UCSF) and a member
of UCSF’s Helen Diller Family Comprehensive Cancer Center. His
primary clinical and research interests center on gastrointestinal
cancers, with a particular emphasis on pancreatic and
gastroesophageal malignancies. He has been responsible for
developing and leading numerous clinical trials evaluating novel
therapeutic strategies for these disease indications (ranging from
novel cytotoxics to molecular targeted agents to immunotherapies)
supported by industry collaborators, the National Cancer Institute,
and various consortia/foundations. His work also entails efforts to
identify individual patient/tumor characteristics that influence
prognosis and response to specific therapies, including both
tissue- and blood-based biomarkers. In addition to his role as
Associate Editor for the Journal of Clinical Oncology since 2016,
he is currently chair of the NCI’s Pancreatic Cancer Task Force;
has served on the scientific program committee, grants committee,
and specialty editorial board for the American Society of Clinical
Oncology (ASCO); has played a leadership role within the GI
Committee of the Alliance for Clinical Trials in Oncology to
shepherd new trial concepts in pancreatic cancer through this
national cooperative group; and sits on the National Comprehensive
Cancer Network Pancreatic Cancer guidelines committee.
About Vincent Picozzi, MD, MMMVincent Picozzi,
MD, MMM is Director for the Pancreas Center of Excellence, Virginia
Mason Digestive Disease and Cancer Institutes, Virginia Mason
Medical Center. A summa cum laude, Phi Beta Kappa graduate from
Yale University, Dr. Picozzi obtained his MD degree from Stanford
University, did his internship and residency at Harvard University
(Brigham and Women’s Hospital), and fellowships in hematology and
oncology again at Stanford. He also holds a masters degree in
medical management Delta Omega, from Tulane University. Dr. Picozzi
was an instructor in hematology and oncology at Stanford for two
years before joining Virginia Mason, where he has been for the past
38 years. Dr. Picozzi directs an active, comprehensive clinical and
translational research program in pancreaticobiliary cancer at
Virginia Mason. He has one of the largest pancreaticobiliary
oncology practices in the United States. He has published over 150
papers and abstracts, and is currently the principal investigator
of 3 registration trials in pancreatic cancer. Dr. Picozzi has been
a featured speaker at virtually every major clinical oncologic
meeting in the United States, including ASCO (the American Society
of Clinical Oncology), ASH (the American Society of Hematology),
ASTRO (the American Society of Therapeutic Radiation Oncology),
Digestive Diseases Week, AHPBA (The American
HepatoPancreaticobiliary Association), ACOS ( the American College
of Surgeons), the Best of ASCO, the GI Oncology Symposium and the
World Pancreas Symposium. Dr. Picozzi also has held a number of
leadership positions with national and regional organizations,
including ASCO, ASH, the American College of Surgeons Oncology
Group (ACOSOG), the Pancreatic Cancer Action Network (PanCAN)
(current board member and formal national chairman), the Pancreas
Cancer Research Team (PCRT-Executive Committee), the Washington
State Medical Oncology Society (WSMOS- Past President x 2), and the
Providence Hospice of Seattle (Executive Board). He is currently
the Co-Principal investigator of the Precision Promise Clinical
Initiative, sponsored by GCAR, in metastatic pancreatic cancer.
About PamrevlumabPamrevlumab is a potential
first-in-class antibody being developed by FibroGen to inhibit the
activity of connective tissue growth factor (CTGF). Pamrevlumab is
in clinical development for the treatment of metastatic pancreatic
cancer and locally advanced unresectable pancreatic cancer (LAPC).
The U.S. Food and Drug Administration has granted Orphan Drug
Designation for the treatment of patients with pancreatic ductal
adenocarcinoma (PDAC), and Fast Track designation to pamrevlumab
for the treatment of patients with LAPC. Pamrevlumab has
demonstrated a safety and tolerability profile that has supported
ongoing clinical investigation in LAPC and metastatic pancreatic
cancer. Pamrevlumab is an investigational drug and not approved for
marketing by any regulatory authority. For information about our
pamrevlumab studies please visit www.clinicaltrials.gov.
About FibroGen FibroGen, Inc. is a
biopharmaceutical company focused on accelerating the development
of novel therapies at the frontiers of cancer biology. Pamrevlumab,
an anti-CTGF fully human monoclonal antibody, is in clinical
development for the treatment of metastatic pancreatic cancer and
locally advanced unresectable pancreatic cancer (LAPC). Roxadustat
(爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and
numerous other countries for the treatment of anemia in chronic
kidney disease (CKD) patients on dialysis and not on dialysis.
Roxadustat is in clinical development for chemotherapy-induced
anemia (CIA) and a Supplemental New Drug Application (sNDA) has
been accepted for review by the China Health Authority. FibroGen
recently expanded its research and development portfolio to include
antibody-drug conjugate (ADC) and immunoncology product candidates
for the treatment of solid tumors. For more information, please
visit www.fibrogen.com.
Forward-Looking Statements This release
contains forward-looking statements regarding FibroGen’s strategy,
future plans and prospects, including statements regarding its
clinical programs and those of its partner, PanCAN. These
forward-looking statements include, but are not limited to,
statements regarding the potential and probability of success of
FibroGen product candidates, and statements about FibroGen’s plans
and objectives and typically are identified by use of terms such as
“may,” “will”, “should,” “on track,” “could,” “expect,” “plan,”
“anticipate,” “believe,” “estimate,” “predict,” “potential,”
“continue” and similar words, although some forward-looking
statements are expressed differently. FibroGen’s actual results may
differ materially from those indicated in these forward-looking
statements due to risks and uncertainties related to the continued
progress and timing of its various programs, including the
enrollment and results from ongoing and potential future clinical
trials, and other matters that are described in FibroGen’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2022,
and our Quarterly Report on Form 10-Q for the quarter ended
September 30, 2023, each as filed with the Securities and Exchange
Commission (SEC), including the risk factors set forth therein.
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release, and FibroGen undertakes no obligation to update any
forward-looking statement in this press release, except as required
by law.
*Pamrevlumab is an investigational drug and not approved for
marketing by any regulatory authority.
FibroGen, Inc.Investors:David
DeLucia, CFAVice President of Corporate FP&A / Investor
Relationsir@fibrogen.com
Media:Meichiel KeenanDirector, Investor
Relations and Corporate Communicationsmedia@fibrogen.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Apr 2024 to May 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From May 2023 to May 2024